According to the Wisdom Financial APP, HOPEWELL-B(02256) rose more than 8% in the afternoon, up 7.14% at HKD 3.45 as of press time, with a turnover of HKD 3.1682 million.

On the news front, recently, Shanghai Allist Pharmaceuticals Co., Ltd. and Hope Medicine jointly announced that clinical research on the combination therapy of absk043, a small molecule PD-L1 inhibitor being developed by Hope Medicine for oral administration, and Allist's self-developed Sulfate-induced gefitinib tablets for advanced non-small cell lung cancer( NSCLC) is about to be carried out.

It is reported that this cooperative research is a multi-center, open phase II clinical trial, including the clinical trial application (IND or CTA) of absk043 combined with gefitinib new drugs, and the exploratory clinical trial of clinical dose climbing and dose extension. The combination of absk043 and gefitinib is expected to bring a better treatment solution for patients with advanced NSCLC.

It is worth noting that recently, some media reported that 19 18A chapter biotech companies (commonly known as B-share) jointly wrote to the Hong Kong Stock Exchange and China Securities Regulatory Commission, hoping that "Hong Kong Stock Connect" can open the door for all B-shares, automatically include them in "Hong Kong Stock Connect", improve the weak liquidity situation, and provide funding for the development of innovative drugs in the mainland.